Production of recombinant protein therapeutics in cultivated mammalian cells
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Cultivated mammalian cells have become the dominant system for the production of recombinant proteins for clinical applications because of their capacity for proper protein folding, assembly and post-translational modification. Thus, the quality and efficacy of a protein can be superior when expressed in mammalian cells versus other hosts such as bacteria, plants and yeast. Recently, the productivity of mammalian cells cultivated in bioreactors has reached the gram per liter range in a number of cases, a more than 100-fold yield improvement over titers seen for similar processes in the mid-1980s. This increase in volumetric productivity has resulted mainly from improvements in media composition and process control. Opportunities still exist for improving mammalian cell systems through further advancements in production systems as well as through vector and host cell engineering.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advances in cell engineering, process control, and media composition are credited with improving the volumetric yield of cell culture bioprocesses, making biopharmaceutical manufacturing more cost-effective and practical [8].”
From The role of Raman spectroscopy in biopharmaceuticals from development to manufacturing (2022) · cites this paper as [8]
In the citing paper
“Chinese hamster ovary (CHO) cells are one of the main cell lines used in the production of recombinant therapeutics (Wurm, 2004; see Grillberger et al., 2009 for examples of proteins produced in CHO cells).”
From Virus susceptibility of Chinese hamster ovary (CHO) cells and detection of viral contaminations by adventitious agent testing (2010) · cites this paper as Wurm, 2004
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451 · cited 1×
“In 1973, Graham and van der Eb showed that exposing cells to nanoparticles of DNA and calcium phosphate makes possible DNA transfer into cultivated mammalian cell”
BackgroundEpigenetic Codes for Heterochromatin Formation and Silencing
Richards, E. J., & Elgin, S. C. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00644-x · Cited by 871
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
How introns influence and enhance eukaryotic gene expression
Le Hir, H., Nott, A., & Moore, M. J. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00052-5 · Cited by 734
Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D., & Yarranton, G. T. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-169 · Cited by 462 · cited 1×
“At a concentration of 10–100 μM MSX, resistant clones can be identified in selected NS0 cell populations that have amplified the transgene complex containing the GS gene and the desired gene(s) of interes”
BackgroundGenetic and physical linkage of exogenous sequences in transformed cells
Perucho, M., Hanahan, D., & Wigler, M. (1980) · Cell · doi:10.1016/0092-8674(80)90178-6 · Cited by 455 · cited 1×
“Nuclear ligases assure the covalent joining of individual plasmid DNA molecule”
BackgroundExpression of recombinant plasmids in mammalian cells Is enhanced by sodium butyrate
Gorman, C. M., Howard, B. H., & Reeves, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.21.7631 · Cited by 367 · cited 1×
“Another way to inhibit silencing is to block deacetylation of histones using butyrat”
BackgroundSilencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9
Mutskov, V., & Felsenfeld, G. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600013 · Cited by 296
Kim, S. J., Kim, N. S., Ryu, C. J., Hong, H. J., & Lee, G. M. (1998) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(19980405)58:1<73::aid-bit8>3.0.co;2-r · Cited by 220 · cited 1×
“Thus, it might be advantageous to omit selective drugs once promising clonal cell lines have been identifie”
BackgroundLarge-scale transient expression in mammalian cells for recombinant protein production
Wurm, F., & Bernard, A. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)80027-5 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Gorman, C.M., Howard, B.H. & Reeves, R. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11, 7631–7648 (1983). · DOI · Paper page
Cited by
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,286
Downstream processing of monoclonal antibodies—Application of platform approaches
Shukla, A. A., Hubbard, B., Tressel, T., Guhan, S., & Low, D. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.09.026 · Cited by 876
The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line
Xu, X., Nagarajan, H., Lewis, N. E., Pan, S., Cai, Z., Liu, X., Chen, W., Xie, M., Wang, W., Hammond, S., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1932 · Cited by 785
“This is consistent with the observation that CHO cells do not normally show ST6Gal activity19, whereas terminal α(2,3)-linked sialic acid residues are abundant.”
InfluentialIntracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Cell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
“Industrial production of mAbs is performed predominantly by recombinant DNA technology, using mammalian cell expression systems,([7,8]) while the first therapeutic mAbs were produced using the hybridoma technique.”
MethodIndustrialization of mAb production technology: The bioprocessing industry at a crossroads
Kelley, B. (2009) · mAbs · doi:10.4161/mabs.1.5.9448 · Cited by 667
Optimal and consistent protein glycosylation in mammalian cell culture
Hossler, P., Khattak, S. F., & Li, Z. J. (2009) · Glycobiology · doi:10.1093/glycob/cwp079 · Cited by 669
Mammalian cell transfection: the present and the future
Kim, T. K., & Eberwine, J. H. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3821-6 · Cited by 678
“The main purpose of transfection is to study the function of genes or gene products, by enhancing or inhibiting specific gene expression in cells, and to produce recombinant proteins in mammalian cells [3].”
BackgroundTransposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration
Klompe, S. E., Vo, P. L. H., Halpin-Healy, T. S., & Sternberg, S. H. (2019) · Nature · doi:10.1038/s41586-019-1323-z · Cited by 627
Recent advances in large-scale production of monoclonal antibodies and related proteins
Shukla, A. A., & Thömmes, J. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.02.001 · Cited by 578
Animal‐cell culture media: History, characteristics, and current issues
Yao, T., & Asayama, Y. (2017) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12024 · Cited by 536
Mammalian cell protein expression for biopharmaceutical production
Zhu, J. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.08.022 · Cited by 491
“…lists available at SciVerse ScienceDirect Biotechnology Advances j ourna l homepage: www.e lsev ie r .com/ locate /b iotechadv (Matasci et al., 2009; Wurm, 2004; Zhang, 2010), plants (Franconi et al., 2010; Pogue et al., 2010; Ruffoni et al., 2011) or animals (Redwan, 2009).”
BackgroundInfluentialConstruction and Characterization of Virus-Like Particles: A Review
Zeltins, A. (2013) · Molecular Biotechnology · doi:10.1007/s12033-012-9598-4 · Cited by 478
“For over two decades, the use of mammalian cell cultures as a source of commercial therapeutic proteins has been developed [70].”
BackgroundBirch, J. R., & Racher, A. J. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.12.006 · Cited by 471
Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals
Butler, M. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1980-8 · Cited by 469
“Cell line transfection and selection The ability to produce and select for a high-producing animal cell line is key to the initial stages of the development of a cell culture bioprocess (Wurm 2004; Andersen and Krummen 2002).”
BackgroundInfluentialHuman cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
Dumont, J., Euwart, D., Mei, B., Estes, S., & Kshirsagar, R. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1084266 · Cited by 483
“Other mammalian cell lines used for the production of biotherapeutic proteins include BHK-21 cells, used in the production of some coagulation factors such as factor VIII (Wurm, 2004).”
BackgroundRecent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
Future of antibody purification
Low, D., O’Leary, R., & Pujar, N. S. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.10.033 · Cited by 472
A Synthetic Optogenetic Transcription Device Enhances Blood-Glucose Homeostasis in Mice
Ye, H., Baba, M. D.-E., Peng, R.-W., & Fussenegger, M. (2011) · Science · doi:10.1126/science.1203535 · Cited by 467
A review of the mammalian unfolded protein response
Chakrabarti, A., Chen, A. W., & Varner, J. D. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23282 · Cited by 409
“Typical mammalian production hosts for this class of product include immortalized Chinese Hamster Ovary (CHO) cells (Wurm, 2004) or other mammalian cell types, such as murine lymphoid cells (NS0, SP2/0) (Khoo et al., 2007).”
BackgroundChahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414
Cell factories for insulin production
Baeshen, N. A., Baeshen, M. N., Sheikh, A., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A. I., Saini, K. S., & Redwan, E. M. (2014) · Microbial Cell Factories · doi:10.1186/s12934-014-0141-0 · Cited by 359
“Recombinant proteins expressed in mammalian cells are properly folded, glycosylated and generally yield a functionally active protein [36].”
BackgroundLight-guiding hydrogels for cell-based sensing and optogenetic synthesis in vivo
Choi, M., Choi, J. W., Kim, S., Nizamoglu, S., Hahn, S. K., & Yun, S. H. (2013) · Nature Photonics · doi:10.1038/nphoton.2013.278 · Cited by 379
“Additionally, genetic and protein engineering to increase the production rate and stability of therapeutic protein will lead to a further reduced implant size 33 .”
Expression of Recombinant Antibodies
Frenzel, A., Hust, M., & Schirrmann, T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00217 · Cited by 353
Analysis of Protein Conformation and Dynamics by Hydrogen/Deuterium Exchange MS
Engen, J. R. (2009) · Analytical Chemistry · doi:10.1021/ac901154s · Cited by 369
Huang, Y., Hu, W., Rustandi, E., Chang, K., Yusuf‐Makagiansar, H., & Ryll, T. (2010) · Biotechnology Progress · doi:10.1002/btpr.436 · Cited by 350
“Nowadays, 1–5 g/L product concentrations or about 200 mg/L/day in volumetric productivity are becoming the typical expectation.(9,10)”
BackgroundTargeted gene knockout in mammalian cells by using engineered zinc-finger nucleases
Santiago, Y., Chan, E., Liu, P.-Q., Orlando, S., Zhang, L., Urnov, F. D., Holmes, M. C., Guschin, D., Waite, A., Miller, J. C., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800940105 · Cited by 358
“system for the production of therapeutic recombinant proteins (17).”
BackgroundGrowth hormone — past, present and future
Ranke, M. B., & Wit, J. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.22 · Cited by 346
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Trends in Upstream and Downstream Process Development for Antibody Manufacturing
Gronemeyer, P., Ditz, R., & Strube, J. (2014) · Bioengineering · doi:10.3390/bioengineering1040188 · Cited by 329
“All development and optimization approaches in USP provide an increase in monoclonal antibody concentration from 50 mg/L in 1986 to 5–20 g/L today [7,8,82].”
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.-R., Santora, L., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1345 · Cited by 344
“Generation of CHO cell lines For clinical applications, a majority of therapeutic proteins are produced in stably transfected mammalian cells, with Chinese hamster ovary (CHO) cells as the most commonly used mammalian host lin”
BackgroundComparison of Yeasts as Hosts for Recombinant Protein Production
Vieira Gomes, A. M., Souza Carmo, T., Silva Carvalho, L., Mendonça Bahia, F., & Parachin, N. S. (2018) · Microorganisms · doi:10.3390/microorganisms6020038 · Cited by 308
Production of virus-like particles for vaccines
Fuenmayor, J., Gòdia, F., & Cervera, L. (2017) · New Biotechnology · doi:10.1016/j.nbt.2017.07.010 · Cited by 318
“Several mammalian cell lines are available for recombinant protein production and are adapted to grow in suspension using serum-free chemically defined media [25].”
The art of CHO cell engineering: A comprehensive retrospect and future perspectives
Fischer, S., Handrick, R., & Otte, K. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.10.015 · Cited by 312
Esmonde-White, K. A., Cuellar, M., Uerpmann, C., Lenain, B., & Lewis, I. R. (2017) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-9824-1 · Cited by 332
“Production of protein therapeutics by mammalian cells is the most widely used bioprocess because of its ability to properly produce and fold a recombinant protein, with 60–70 % of biopharmaceuticals using this bioprocess [79, 80].”
BackgroundBaldi, L., Hacker, D. L., Adam, M., & Wurm, F. M. (2007) · Biotechnology Letters · doi:10.1007/s10529-006-9297-y · Cited by 312
“Despite these advances, the specific productivity of TGE remains typically far below 10 pg/cell day, whereas that of some recombinant cell lines has been reported to be over 50 pg/cell day (Wurm 2004).”
BackgroundInfluentialSelf-citationA general approach to site-specific antibody drug conjugates
Tian, F., Lu, Y., Manibusan, A., Sellers, A., Tran, H., Sun, Y., Phuong, T., Barnett, R., Hehli, B., Song, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321237111 · Cited by 319
“From the platform cell line 4E2, first-generation stable cell lines expressing the mutant Ab A1 HC-A114pAF (Scheme S1) (Kabat numbering) were generated using Lonza’s GS Ab expression system (21) with a methionine sulfoximine (MSX) concentration of 50 μM.”
MethodAdvances in Mammalian cell line development technologies for recombinant protein production
Lai, T., Yang, Y., & Ng, S. (2013) · Pharmaceuticals · doi:10.3390/ph6050579 · Cited by 322
“The strategy is limited by the inefficiency of co-transfection and the reliability of product expression based on the selection of the cotransfected marker gene can be very low [20].”
BackgroundA study of monoclonal antibody‐producing CHO cell lines: What makes a stable high producer?
Chusainow, J., Yang, Y. S., Yeo, J. H. M., Toh, P. C., Asvadi, P., Wong, N. S. C., & Yap, M. G. S. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22158 · Cited by 313
“Stability of these cell lines in the absence of selection pressure is important to ensure predictable high recombinant protein yields during production (Wurm, 2004).”
BackgroundDesigning cell function: assembly of synthetic gene circuits for cell biology applications
Xie, M., & Fussenegger, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0024-z · Cited by 285
Lactate supports a metabolic-epigenetic link in macrophage polarization
Noe, J. T., Rendon, B. E., Geller, A. E., Conroy, L. R., Morrissey, S. M., Young, L. E. A., Bruntz, R. C., Kim, E. J., Wise-Mitchell, A., Barbosa de Souza Rizzo, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi8602 · Cited by 283
“6 of 12 “lactate metabolic shift” where lactate is oxidized to maintain bioenergetics needed for cellular viability (38, 39).”
BackgroundThe growth and potential of human antiviral monoclonal antibody therapeutics
Marasco, W. A., & Sui, J. (2007) · Nature Biotechnology · doi:10.1038/nbt1363 · Cited by 284
“The productivity of mammalian cells cultivated in bioreactors is now one gram per liter and in several cases, a more than 100-fold improvement over titers for similar processes in the mid-1980s has been realize”
BackgroundPerfusion mammalian cell culture for recombinant protein manufacturing – A critical review
Bielser, J.-M., Wolf, M., Souquet, J., Broly, H., & Morbidelli, M. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.011 · Cited by 263
“…in constant evolution since the first biological drug manufactured in recombinant mammalian cells was commercialized in 1986 (Ecker et al., 2015; Wurm, 2004), a more profound mindset evolution is being discussed for some time among the scientific community: the transition of traditional batch…”
BackgroundRitacco, F. V., Wu, Y., & Khetan, A. (2018) · Biotechnology Progress · doi:10.1002/btpr.2706 · Cited by 273
Preventing unintended proteolysis in plant protein biofactories
Benchabane, M., Goulet, C., Rivard, D., Faye, L., Gomord, V., & Michaud, D. (2008) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2008.00344.x · Cited by 244
“A number of heterologous expression systems have been devised over the last decade for the production of clinically useful recombinant proteins, involving, in most cases, eukaryotic hosts competent in performing complex posttranslational modifications typical of mammalian proteins (Dyck et al ., 2003; Ma et al ., 2003…”
BackgroundProduction of heterologous proteins in plants: Strategies for optimal expression
Desai, P. N., Shrivastava, N., & Padh, H. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.01.005 · Cited by 242
“…(e)Walsh, 2003; (f)Wildt & Gernfross, 2005; (g) Smith et al., 1983; (h) Donald & Ja al., 1988; (m) Echelard et al., 2006; (n) Moreira, 2007; (o) Wurm, 2004. heterologous proteins are a gene or cDNA encoding desired protein, a suitable vector and a biological system (expression system) which…”
BackgroundImpact of host cell line choice on glycan profile
Goh, J. B., & Ng, S. K. (2018) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1416577 · Cited by 225
“As mammalian cells are the predominant expression systems for over 60% of recombinant protein pharmaceuticals [51], we review the glycosylation potential of various mammalian host cells in the following sections.”
BackgroundSelection methods for high-producing mammalian cell lines
Browne, S. M., & Al-Rubeai, M. (2007) · Trends in Biotechnology · doi:10.1016/j.tibtech.2007.07.002 · Cited by 237
Hysteresis in a synthetic mammalian gene network
Kramer, B. P., & Fussenegger, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500345102 · Cited by 240
Macromolecular diffusion and release from self-assembled β-hairpin peptide hydrogels
Branco, M. C., Pochan, D. J., Wagner, N. J., & Schneider, J. P. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.11.019 · Cited by 231
Protein Hydrolysates in Biotechnology
(2010) · Springer eBooks · doi:10.1007/978-1-4020-6674-0 · Cited by 226
GMP issues for recombinant plant-derived pharmaceutical proteins
Fischer, R., Schillberg, S., Hellwig, S., Twyman, R. M., & Drossard, J. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.08.007 · Cited by 228
“For complex human proteins such as glycoproteins, mammalian cells were the only viable platform for nearly 20 years, and naturally the regulations for drug manufacturing had developed alongside this platform and were tailored in its favor (Wurm, 2004).”
BackgroundO’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107552 · Cited by 277
Backliwal, G., Hildinger, M., Chenuet, S., Wulhfard, S., De Jesus, M., & Wurm, F. M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn423 · Cited by 226
“However, the major bottlenecks in transient transfection are low titers and low specific productivity compared to stable cell lines (7,8): whereas transient transfection yields titers in the range of 20–40 mg/l with a specific productivity of 1–4 pg/cell/day, stable cell lines reach 1–2 g/l with a specific productivit…”
BackgroundSelf-citationβ-cell–mimetic designer cells provide closed-loop glycemic control
Xie, M., Ye, H., Wang, H., Charpin-El Hamri, G., Lormeau, C., Saxena, P., Stelling, J., & Fussenegger, M. (2016) · Science · doi:10.1126/science.aaf4006 · Cited by 224
Lactate metabolism shift in CHO cell culture: the role of mitochondrial oxidative activity
Zagari, F., Jordan, M., Stettler, M., Broly, H., & Wurm, F. M. (2013) · New Biotechnology · doi:10.1016/j.nbt.2012.05.021 · Cited by 202
Self-citationNon-genetic engineering of cells for drug delivery and cell-based therapy
Wang, Q., Cheng, H., Peng, H., Zhou, H., Li, P. Y., & Langer, R. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.003 · Cited by 225
Process analytical technology (PAT) for biopharmaceuticals
Glassey, J., Gernaey, K. V., Clemens, C., Schulz, T. W., Oliveira, R., Striedner, G., & Mandenius, C. (2011) · Biotechnology Journal · doi:10.1002/biot.201000356 · Cited by 211
“Wurm [35] reported that 60–70% of all recombinant protein pharmaceuticals are produced in mammalian cells, usually following a well-established production scheme.”
BackgroundRecent advances in mammalian protein production
Bandaranayake, A. D., & Almo, S. C. (2014) · FEBS Letters · doi:10.1016/j.febslet.2013.11.035 · Cited by 222
Berlec, A., & Štrukelj, B. (2013) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-013-1235-0 · Cited by 211
“The viability of cells can be improved by introducing proto-oncogenes and growth factor genes [138].”
BackgroundInfluentialAlsaker, K. V., Paredes, C., & Papoutsakis, E. T. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22628 · Cited by 213
Instructive microenvironments in skin wound healing: Biomaterials as signal releasing platforms
Castaño, O., Pérez-Amodio, S., Navarro-Requena, C., Mateos-Timoneda, M. Á., & Engel, E. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.012 · Cited by 218
Kim, M., O'Callaghan, P. M., Droms, K. A., & James, D. C. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23189 · Cited by 215
“The generation of a recombinant mammalian cell line producing high levels of a therapeutic protein in an industrial bioreactor is a resource intensive process involving several months of work (Wurm, 2004).”
BackgroundIntraclonal Protein Expression Heterogeneity in Recombinant CHO Cells
Pilbrough, W., Munro, T. P., & Gray, P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008432 · Cited by 200
“integration of expression vectors into the host genome [6].”
BackgroundPlants as sources of natural and recombinant anti-cancer agents
Buyel, J. F. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.02.002 · Cited by 204
Jäger, V., Büssow, K., Wagner, A., Weber, S., Hust, M., Frenzel, A., & Schirrmann, T. (2013) · BMC Biotechnology · doi:10.1186/1472-6750-13-52 · Cited by 200
“Industrial IgG production levels in Chinese hamster ovary (CHO) cells reached about 5 g/L some years ago [25] whereas today titers often exceed 12 g/L as result of a steadily ongoing progress of mammalian cell culture technology which is mainly due to improved high producer cell lines, optimized serum-free production…”
BackgroundKwon, H., Kim, M., Seo, Y., Moon, Y. S., Lee, H. J., Lee, K., & Lee, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.034 · Cited by 208
Transgenic plants in the biopharmaceutical market
Twyman, R. M., Schillberg, S., & Fischer, R. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.1.185 · Cited by 206
Lee, J. S., Kallehauge, T. B., Pedersen, L. E., & Kildegaard, H. F. (2015) · Scientific Reports · doi:10.1038/srep08572 · Cited by 195
Kauper, K., McGovern, C., Sherman, S., Heatherton, P., Rapoza, R., Stabila, P., Dean, B., Lee, A., Borges, S., Bouchard, B., et al. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9970 · Cited by 192
“The levels of protein produced, and the potency of the protein engineered, can be optimized with the ECT platform cell line as in many mammalian biologic production cell lines.(34) Optimization of other components of the ECT system, such as the permeability of the membrane and the internal volume of the ECT device, is…”
BackgroundPutting the Spotlight Back on Plant Suspension Cultures
Santos, R. B., Abranches, R., Fischer, R., Sack, M., & Holland, T. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00297 · Cited by 189
“In contrast to CHO cells, where medium optimization needs to be done for each product and cell line on a case-by-case basis (Wurm, 2004), for plant cell cultures it appears to similarly benefit all products (Holland et al., 2010; Ullisch et al., 2012).”
BackgroundMethodBioseparation in Antibody Manufacturing: The Good, The Bad and The Ugly
Gottschalk, U. (2008) · Biotechnology Progress · doi:10.1021/bp070452g · Cited by 188
Levy, N. E., Valente, K. N., Choe, L. H., Lee, K. H., & Lenhoff, A. M. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25158 · Cited by 183
Strategies for high-level recombinant protein expression in transgenic microalgae: A review
Potvin, G., & Zhang, Z. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.08.006 · Cited by 188
25 years of recombinant proteins from reactor-grown cells — Where do we go from here?
Hacker, D. L., De Jesus, M., & Wurm, F. M. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.05.008 · Cited by 177
Self-citationHeat-stable oral alga-based vaccine protects mice from Staphylococcus aureus infection
Dreesen, I. A. J., Hamri, G. C.-E., & Fussenegger, M. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2009.12.006 · Cited by 177
Guidelines to cell engineering for monoclonal antibody production
Rita Costa, A., Elisa Rodrigues, M., Henriques, M., Azeredo, J., & Oliveira, R. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.10.002 · Cited by 178
“Indeed, it has been shown that the site of integration mostly influences the transcription rate of the recombinant gene, a phenomenon known as the position effect [27,61].”
BackgroundInfluentialHuman cells: new platform for recombinant therapeutic protein production
Swiech, K., Picanço-Castro, V., & Covas, D. T. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2012.04.023 · Cited by 178
“Therefore, what will be the contribution of the human cells production platform and the differences between this and the traditional expression systems? The main difference of the today’s bioprocess and the first’s one is the specific and volumetric productivity, which increased from 10–20 pg/cell/day and 50–100 mg/L…”
BackgroundRademacher, T., Sack, M., Arcalis, E., Stadlmann, J., Balzer, S., Altmann, F., Quendler, H., Stiegler, G., Kunert, R., Fischer, R., et al. (2008) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2007.00306.x · Cited by 174
Pros and cons of different therapeutic antibody formats for recombinant antivenom development
Laustsen, A. H., María Gutiérrez, J., Knudsen, C., Johansen, K. H., Bermúdez-Méndez, E., Cerni, F. A., Jürgensen, J. A., Ledsgaard, L., Martos-Esteban, A., Øhlenschlæger, M., et al. (2018) · Toxicon · doi:10.1016/j.toxicon.2018.03.004 · Cited by 177
“For production of therapeutic antibodies, mammalian cell lines are often chosen as the expression organism (Berlec and Strukelj, 2013; Wurm, 2004).”
BackgroundBackliwal, G., Hildinger, M., Kuettel, I., Delegrange, F., Hacker, D. L., & Wurm, F. M. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21882 · Cited by 170
Self-citationOptimized signal peptides for the development of high expressing CHO cell lines
Kober, L., Zehe, C., & Bode, J. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.24776 · Cited by 165
Zrimec, J., Börlin, C. S., Buric, F., Muhammad, A. S., Chen, R., Siewers, V., Verendel, V., Nielsen, J., Töpel, M., & Zelezniak, A. (2020) · Nature Communications · doi:10.1038/s41467-020-19921-4 · Cited by 174
Gene expression is encoded in all parts of a co-evolving interacting gene regulatory structure
Zrimec, J., Buric, F., Muhammad, A. S., Chen, R., Verendel, V., Töpel, M., & Zelezniak, A. (2019) · doi:10.1101/792531 · Cited by 173
Exploring the potential of genome editing CRISPR-Cas9 technology
Singh, V., Braddick, D., & Dhar, P. K. (2017) · Gene · doi:10.1016/j.gene.2016.11.008 · Cited by 160
“In the past decade, mammalian cells have posed an increasingly more attractive proposition for the production of recombinant proteins and therapeutics because of their superior capabilities for protein folding, assembly, and post-translational modification (Wurm, 2004).”
BackgroundManufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors
De Jesus, M., & Wurm, F. M. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.01.005 · Cited by 160
“In the late 1980s, a typical batch culture production run lasted about 7 days with a maximum cell density of 1–2 million cells/ml, and the usual yield was 50–100 mg/l [54].”
BackgroundSelf-citationBAK and BAX deletion using zinc‐finger nucleases yields apoptosis‐resistant CHO cells
Cost, G. J., Freyvert, Y., Vafiadis, A., Santiago, Y., Miller, J. C., Rebar, E., Collingwood, T. N., Snowden, A., & Gregory, P. D. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22541 · Cited by 160
Insertion of the Designed Helical Linker Led to Increased Expression of Tf-Based Fusion Proteins
Amet, N., Lee, H.-F., & Shen, W.-C. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9767-0 · Cited by 163
“Since mammalian cells are the preferred choice for producing some therapeutic proteins, as posttranslational modifications in these cells may be associated with reduced immunogenicity compared to other systems (3), a simple strategy that enhances the expression of therapeutic fusion proteins in mammalian cells would b…”
Membrane-less microfiltration using inertial microfluidics
Warkiani, M. E., Tay, A. K. P., Guan, G., & Han, J. (2015) · Scientific Reports · doi:10.1038/srep11018 · Cited by 162
Marichal‐Gallardo, P., & Álvarez, M. M. (2012) · Biotechnology Progress · doi:10.1002/btpr.1567 · Cited by 166
“Mammalian cells have become the dominant expression system for recombinant proteins destined for clinical use due to their abilities for proper assembly, folding, and post-translational modifications.(22,23) The use of high-titer chinese hamster ovary (CHO) cell cultures in combination with modern chromatography resin…”
BackgroundThe potential of hydrodynamic damage to animal cells of industrial relevance: current understanding
Hu, W., Berdugo, C., & Chalmers, J. J. (2011) · Cytotechnology · doi:10.1007/s10616-011-9368-3 · Cited by 183
“As was recently summarized in a review by Wurm (2004) , between 1986 and 2004, the final product concentrations have increased approximately 100 fold, the final cell density approximately 10 fold, and the specific productivities increased from about 10 pg/cell/day to 90 pg/cell/day.”
BackgroundKandel, M. E., He, Y. R., Lee, Y. J., Chen, T. H.-Y., Sullivan, K. M., Aydin, O., Saif, M. T. A., Kong, H., Sobh, N., & Popescu, G. (2020) · Nature Communications · doi:10.1038/s41467-020-20062-x · Cited by 180
Upstream processes in antibody production: Evaluation of critical parameters
Jain, E., & Kumar, A. (2007) · Biotechnology Advances · doi:10.1016/j.biotechadv.2007.09.004 · Cited by 179
A multi-landing pad DNA integration platform for mammalian cell engineering
Gaidukov, L., Wroblewska, L., Teague, B., Nelson, T., Zhang, X., Liu, Y., Jagtap, K., Mamo, S., Tseng, W. A., Lowe, A., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky216 · Cited by 160
Protein-Engineered Biomaterials: Highly Tunable Tissue Engineering Scaffolds
Sengupta, D., & Heilshorn, S. C. (2010) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2009.0591 · Cited by 158
Dahodwala, H., & Lee, K. H. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.011 · Cited by 154
“Chinese hamster ovary (CHO) cell lines have been preferentially used to produce recombinant therapeutics and are used for manufacturing approximately 70% of all recombinant biopharmaceutical proteins and for all mAbs (adalimumab, bezlotoxumab, avelumab, dupilumab, durvalumab ocrelizumab, and brodalumab) approved since…”
BackgroundPerspectives for clinical use of engineered human host defense antimicrobial peptides
Pachón-Ibáñez, M. E., Smani, Y., Pachón, J., & Sánchez-Céspedes, J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux012 · Cited by 159
“With the techniques employed nowadays, the improvements inmedia composition, and bioprocess developments, volumetric productivity can be achieved up to 1–5 g L−1 (Wurm 2004).”
MethodFath, S., Bauer, A. P., Liss, M., Spriestersbach, A., Maertens, B., Hahn, P., Ludwig, C., Schäfer, F., Graf, M., & Wagner, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017596 · Cited by 158
“most proteins used for vaccination, human therapy or diagnostics are currently produced in mammalian cells [5].”
BackgroundGlycosylation: impact, control and improvement during therapeutic protein production
Costa, A. R., Rodrigues, M. E., Henriques, M., Oliveira, R., & Azeredo, J. (2014) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.793649 · Cited by 155
Metadata
- Authors
- Wurm, F. M.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Wurm, Florian M
- ORCID
- Wurm, Florian M
- Venue
- Nature Biotechnology
- Published
- 2004-11
- Volume
- 22
- Issue
- 11
- Pages
- 1393-1398
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2118540273
- Cited by
- 2,032
- References
- 52
- Citations by year
- 2026: 52 · 2025: 51 · 2024: 66 · 2023: 66 · 2022: 64 · 2021: 77 · 2020: 89 · 2019: 114 · 2018: 162 · 2017: 118 · 2016: 95 · 2015: 135 · 2014: 108 · 2013: 145 · 2012: 111
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
- Keywords
- recombinant therapeutic proteins, mammalian cell culture, bioreactors, protein folding, post-translational modification, volumetric productivity, culture medium optimization, process control, vector engineering, host cell engineering
- MeSH terms
- Animals, Cells, Cultured, Humans, Mammals, Recombinant Proteins, Transfection, Protein Engineering, Cell Culture Techniques, Bioreactors, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.